Spots Global Cancer Trial Database for Identification of Hepatic Lesions
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Identification of Hepatic Lesions
Official Title: A Prospective, Multicenter, Phase III b Clinical Study to Evaluate the Effectiveness of Unenhanced and SH U 555A (Resovist) Enhanced MRI, Compared to Contrast-Enhanced Dual-Phase Spiral CT in Assessing the Correct Final Therapy-Deciding Diagnosis, in Patients With Primary or Secondary Hepatic Malignancies.
Study ID: NCT00307866
Conditions
Interventions
Study Description
Brief Summary: Patients with suspicion of primary or secondary hepatic malignancy in whom a radiological examination is needed in order to decide on the most appropriate treatment.
Detailed Description: The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany. Bayer Schering Pharma AG, Germany is the sponsor of the trial.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
, Bari, BA, Italy
, Bologna, BO, Italy
, Brescia, BS, Italy
, Firenze, FI, Italy
, Genova, GE, Italy
, Milano, MI, Italy
, Milano, MI, Italy
, Milano, MI, Italy
, Palermo, PA, Italy
, Pisa, PI, Italy
, Sassari, SS, Italy
, Torino, TO, Italy
, Trieste, TS, Italy
, Verona, VE, Italy
, Chieti, , Italy
, L'Aquila, , Italy
, Roma, , Italy
, Roma, , Italy
, Udine, , Italy
Contact Details
Name: Bayer Study Director
Affiliation: Bayer
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
